脑干对流增强给药中皮质脊髓束的临床耐受性
该研究基于一项弥漫性内生型脑桥胶质瘤(DIPG)对流增强给药(CED)的Ⅰ期临床试验(NCT01502917),分析31例患者39次导管置入中导管与皮质脊髓束(CST)相交及分布容积(Vd)与CST重叠和运动功能缺损的关系,结论为经幕上入路跨越CST导致1例神经功能缺损加重,未见需在导管轨迹规划中避开优势运动纤维束的显著风险,Vd与CST重叠与神经不良事件无相关性。
要点
- 31例DIPG患者共39次CED导管置入,平均年龄7.6岁(范围3.2-18岁)。
- 导管与CST平均相交2.2次(范围0-3),平均相交长度18.9 mm(范围0-44.2 mm)。
- 最高剂量组Vd与CST平均重叠5.5 cm3,Vd-CST重叠与神经不良事件无相关性。
核心结论
- 经幕上入路跨越CST置管导致1例神经功能缺损加重。
- 似乎不存在需要在导管轨迹规划中避开优势运动纤维束的显著风险。
- 本队列中Vd与CST重叠与神经不良事件无相关性。
研究设计与样本
- CED治疗DIPG的Ⅰ期临床试验(注册号NCT01502917,clinicaltrials.gov)中的影像分析。
- 2012年至2017年共31例患者、39次导管置入,置入柔性输注导管并以MRI引导输注124I-8H9。
- 分析术中及术后MRI以识别导管轨迹及T2加权信号强度变化以估算Vd。
- 记录导管与CST相交及Vd与CST重叠,并评估其与运动功能缺损的相关性。
主要发现
- 31例患者平均年龄7.6岁(范围3.2-18岁),共39次导管置入;30次导管置入有可供分析的白质纤维束成像数据。
- 平均轨迹长度105.5 mm(范围92.7-121.6 mm)。
- 导管与CST平均相交2.2次(范围0-3),平均相交长度18.9 mm(范围0-44.2 mm)。
- 最高剂量水平前9次输注(输注液量范围3.84-4.54 ml)分析Vd与CST重叠:该组平均年龄7.6岁(范围5.8-10.3岁),平均轨迹长度109.5 mm(范围102.6-122.3 mm),Vd与CST平均重叠5.5 cm3。
- 置管相关不良事件:1例(3%)术后对侧面神经麻痹加重,伴2次CST相交、相交距离31.7 mm、Vd与CST重叠3.64 cm3。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Convection-enhanced delivery (CED) has been explored as a therapeutic strategy for diffuse intrinsic pontine glioma (DIPG). Variables that may affect tolerance include infusate volume, infusion rate, catheter trajectory, and target position. Supratentorial approaches for catheter placement and infusate distribution patterns may conflict with corticospinal tracts (CSTs). The clinical relevance of these anatomical constraints has not been described. The authors report their experience using CED in the brainstem as it relates to anatomical CST conflict and association with clinical tolerance. METHODS: In a phase I clinical trial of CED for DIPG (clinical trial registration no. NCT01502917, clinicaltrials.gov), a flexible infusion catheter was placed with MRI guidance for infusion of 124I-8H9, a radioimmunotherapeutic agent. Intra- and postprocedural MR images were analyzed to identify catheter trajectories and changes in T2-weighted signal intensity to approximate volume of distribution (Vd). Intersection of CST by the catheter and overlap between Vd and CST were recorded and their correlation with motor deficits was evaluated. RESULTS: Thirty-one patients with a mean age of 7.6 years (range 3.2-18 years) underwent 39 catheter insertions for CED between 2012 and 2017. Thirty catheter insertions had tractography data available for analysis. The mean trajectory length was 105.5 mm (range 92.7-121.6 mm). The mean number of intersections of CST by catheter was 2.2 (range 0-3) and the mean intersecting length was 18.9 mm (range 0-44.2 mm). The first 9 infusions in the highest dose level (range 3.84-4.54 ml infusate) were analyzed for Vd overlap with CST. In this group, the mean age was 7.6 years (range 5.8-10.3 years), the mean trajectory length was 109.5 mm (range 102.6-122.3 mm), and the mean overlap between Vd and CST was 5.5 cm3. For catheter placement-related adverse events, 1 patient (3%) had worsening of a contralateral facial nerve palsy following the procedure with two CST intersections, an intersecting distance of 31.7 mm, and an overlap between Vd and CST of 3.64 cm3. For infusion-related adverse events, transient postinfusion deficits were noted in 3 patients in the highest dose level, with a mean number of 2 intersections of CST by catheter, mean intersecting length of 12.9 mm, and mean overlap between Vd and CST of 6.3 cm3. CONCLUSIONS: A supratentorial approach to the brainstem crossing the CST resulted in one worsened neurological deficit. There does not appear to be a significant risk requiring avoidance of dominant motor fiber tracts with catheter trajectory planning. There was no correlation between Vd-CST overlap and neurological adverse events in this cohort.Clinical trial registration no.: NCT01502917 (clinicaltrials.gov).
引用
- Morgenstern PF, Zhou Z, Wembacher-Schröder E, et al. Clinical tolerance of corticospinal tracts in convection-enhanced delivery to the brainstem. J Neurosurg. 2018. PMID: 30579270. doi:10.3171/2018.6.JNS18854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。